ISSN: 2044-9038 (Print) 2044-9046 (Electronic)

Clinical Practice

Pharmacogenomics Related Journals

 Pharmacogenomics is the branch of study of the role of genetics in drug response. The related Journals are Clinical & Experimental Pharmacology, Journal of Pharmacogenomics & Pharmacoproteomics, American Journal of Pharmacogenomics, Journal of Molecular Pharmaceutics & biological process Research, Journal of Proteomics & Bioinformatics. The Journal of Neurobehavioral Sciences. Journal of pharmacogenomics and Pharmacoproteomics. Pharmacogenomics is one of the doors to enter the complex building of personalized medicine. The introduction of pharmacogenomics in drug development and therefore the inclusion of pharmacogenomic information on drug labels, with specific warnings for the population in danger. Pharmacogenomics results for ≈80% variability in drug efficacy and safety. In cardiovascular disorders, the most concern is response to drugs including warfarin, clopidogrel, beta blockers, and statins. In patients with CYP2C19, who take clopidogrel, cardiovascular risk is elevated, leading to medication package insert updates by regulators. In patients with type 2 diabetes, haptoglobin (Hp) genotyping shows an effect on cardiovascular disease, with Hp2-2 at higher risk and supplemental vitamin E reducing risk by affecting HDL. In psychiatry, as of 2010, research has focused particularly on 5-HTTLPR and DRD2. The term pharmacogenetic was first coined in 1959 by Friedrich Vogel of Heidelberg, Germany (although some papers suggest it had been 1957 or 1958). In the late 1960s, twin studies supported the inference of genetic involvement in drug metabolism, with identical twins sharing remarkable similarities to drug response compared to fraternal twins.[18] The term pharmacogenomics first began appearing around the 1990s.  

High Impact List of Articles

Relevant Topics in Clinical